{"type":"trials","record":{"id":41583,"source_id":"clinicaltrials-gov","external_id":"NCT03630562","title":"Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration","brief_summary":"Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Centre Hospitalier Universitaire de Nice","enrollment":100,"countries":["France"],"start_date":"2018-11-26","completion_date":"2021-08-19","last_update_date":"2026-03-24","source_url":"https://clinicaltrials.gov/study/NCT03630562","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"TARMAC-1","age_range":"18 Years","comparator":null,"organization":"Centre Hospitalier Universitaire de Nice","interventions":["Aqueous humor samples collection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months — At M…","Dose of VEGF in the aqueous humor of patients with exudative AMD — At Day 0, Month 1, Month 2, Month 3","Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD — At Day 0, Month 1, Month 2, Mo…","Measurement of visual acuity with Snellen chart — At Day 0, Month 1, Month 2, Month 3","Measurement of visual acuity with ETDRS visual acuity chart — At Day 0, Month 1, Month 2, Month 3"],"design_description":"NA · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["Age Related Macular Degeneration","Aqueous humor samples collection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03630562","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2018-11-26 to 2021-08-19","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.837Z","intervention":["Aqueous humor samples collection"],"participants":100,"study_design":"NA · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months — At M…","Dose of VEGF in the aqueous humor of patients with exudative AMD — At Day 0, Month 1, Month 2, Month 3","Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD — At Day 0, Month 1, Month 2, Mo…","Measurement of visual acuity with Snellen chart — At Day 0, Month 1, Month 2, Month 3","Measurement of visual acuity with ETDRS visual acuity chart — At Day 0, Month 1, Month 2, Month 3"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41583","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}